Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1993:82 Suppl 5:111-8.

[Operation and angioplasty in peripheral arterial occlusive disease]

[Article in German]
Affiliations
  • PMID: 8154149
Review

[Operation and angioplasty in peripheral arterial occlusive disease]

[Article in German]
M P Heintzen et al. Z Kardiol. 1993.

Abstract

The treatment of peripheral arterial occlusive disease is based on conservative treatment, surgical revascularization, and percutaneous transluminal catheter-based methods. The differential indication for treatment is mainly influenced by clinical and angiographic parameters. The indications for surgical and catheter-based revascularization are relatively clear: Short occlusions and stenoses of the iliac and femoropopliteal arteries in symptomatic patients are ideal indications for PTA. In patients with critical leg ischemia percutaneous revascularization techniques should always be considered to treat these patients with the minimal invasive approach. Long occlusions of iliac and femoral arteries and diffuse occlusions of multiple segments in patients with severe claudication, ischemic rest pain or gangrene are best treated by primary surgical revascularization. Beside the established percutaneous transluminal balloon angioplasty several new interventional techniques were developed to extend the indications for percutaneous treatment, improve acute success rates and reduce complications. Probably, also long-term results after catheter-based therapy of peripheral arterial occlusive disease may be improved by these new technologies.

PubMed Disclaimer